Effect Of Percutaneous Electrical Nerve Field Stimulation on Symptom Control/Nervous System Activity in Patients w/Diabetes Types 1/2

Prior treatment

• History of prior gastric surgery
• Those at high surgical risk

Other illness

• Diagnosed with cardiac arrhythmia
• History of vagotomy
• History of organ transplantation
• History of seizures
• Diagnosed with primary swallowing disorders
• Subjects who are dependent on drugs like Marinol for their condition
• Those with poorly controlled diabetes mellitus (Hgb A1c\>8) within three months of screening or at the time of screening.
• Those having a cardiac pacemaker will be excluded from the study.

Other

• Unable to provide consent
• Pregnant females
• Medical records indicate intestinal pseudo-obstruction
• Those diagnosed with psychogenic vomiting and not related to gastroparesis
• Medically unstable subjects
• Subjects taking narcotic analgesics daily.
• Subjects diagnosed with hemophilia, psoriasis vulgaris are excluded

• Wiling to have one teaspoon (5 ml) of blood drawn.
• Willing to have electrodes placed in the external ear.
• Diagnosed with gastroparesis for twelve months or longer
• Diagnosed with diabetes either Type 1 or Type 2
• Documented delayed gastric emptying (\>10% retention of the test meal at four hours) on a standardized scrambled-egg scintigraphy gastric emptying test performed in the last two years.
• Upper GI endoscopy indicating no mechanical obstruction performed in the last five years.
• Symptoms of nausea and vomiting consistent with clinical diagnosis of gastroparesis (as opposed to other causes of nausea and vomiting such as mechanical obstruction, acute viral illness, chemotherapy, psychogenic vomiting.
• Documented Hb A1c within three months of screening or at the time of screening (\<=8.0)